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Cell-type dependent enhancer binding of the EWS/
ATF1 fusion gene in clear cell sarcomas
Shingo Komura1,2,13, Kenji Ito1,3,13, Sho Ohta3, Tomoyo Ukai3, Mio Kabata1, Fumiaki Itakura1, Katsunori Semi1,
Yutaka Matsuda1,4, Kyoichi Hashimoto1, Hirofumi Shibata1, Masamitsu Sone1, Norihide Jo1, Kazuya Sekiguchi1,5,6,
Takatoshi Ohno2, Haruhiko Akiyama2, Katsuji Shimizu7, Knut Woltjen 1,8, Manabu Ozawa9,
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Clear cell sarcoma (CCS) is a rare soft tissue sarcoma caused by the EWS/ATF1 fusion gene.
Here, we established induced pluripotent stem cells (iPSCs) from EWS/ATF1-controllable
murine CCS cells harboring sarcoma-associated genetic abnormalities. Sarcoma-iPSC mice
develop secondary sarcomas immediately after EWS/ATF1 induction, but only in soft tissue.
EWS/ATF1 expression induces oncogene-induced senescence in most cell types in sarcoma-
iPSC mice but prevents it in sarcoma cells. We identify Tppp3-expressing cells in peripheral
nerves as a cell-of-origin for these sarcomas. We show cell type-specific recruitment of
EWS/ATF1 to enhancer regions in CCS cells. Finally, epigenetic silencing at these enhancers
induces senescence and inhibits CCS cell growth through altered EWS/ATF1 binding.
Together, we propose that distinct responses to premature senescence are the basis for the
cell type-specificity of cancer development.
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Cell-type-specific development of cancer has long beenrecognized. Here, specific genes are mutated in particulartypes of cancer, and patients harboring germline muta-
tions at tumor suppressor genes, such as APC and BRCA1/
BRCA2, exclusively develop cancers in specific organs1–3. Simi-
larly, differentiation status-dependent cancer development has
been reported in several cancers4,5. Given that epigenetic reg-
ulations play a central role in differentiation and cell fate main-
tenance, these findings suggest that a coordinated action of the
cancer genome and cellular context-dependent epigenetic reg-
ulations is required for cancer development. However, it is
unclear how the cellular context-dependent epigenetic regulations
affect cancer development and progression.
Clear-cell sarcoma (CCS) is a rare tumor and preferentially
arises in soft tissue in the extremities. CCS often harbors mela-
nocytic properties, and thus resembles malignant melanoma6,7.
Despite their shared properties, CCS is distinguished from
malignant melanoma by the presence of a specific fusion onco-
gene, EWS/ATF1, which results from a reciprocal translocation, t
(12;22)(q13;q12)8. Previous in vivo studies using EWS/ATF1-
inducible CCS model demonstrated that EWS/ATF1 is a key
driver oncogene in both the development and maintenance of the
sarcomas9,10. Straessler et al.10 demonstrated that EWS/ATF1 can
transform mesenchymal progenitor cells10, while our previous
study suggested that the sarcomas arose from neural crest-derived
cells9. However, given that mesenchymal progenitor cells and
neural crest-derived cells contain diverse cell types, a cell of origin
for this sarcoma remains to be fully understood.
In the present study, we establish induced pluripotent stem
cells (iPSCs) from murine CCS cell lines that harbor sarcoma-
associated genetic abnormalities and differentiate them into a
wide variety of cell types in vivo via the generation of chimeric
mice. The chimeric mice rapidly develop secondary sarcomas in a
cell-type-dependent manner, which is associated with a cell-type-
specific response to premature senescence. Utilizing the one-step
and cell-type-specific sarcoma model, we identify Tppp3-expres-
sing peripheral nerve cell as a cell type that gives rise to CCSs and
demonstrate that cellular context-dependent epigenetic regula-
tions, in conjunction with genetic abnormalities, play a funda-
mental role in the maintenance of the malignant phenotype and
thus can be a therapeutic target in sarcoma cells.
Results
Establishment of iPSCs from EWS/ATF1-induced sarcoma
cells. To establish iPSCs, we introduced OCT3/4, SOX2, KLF4 and
cMYC into a murine CCS cell line (G1297) containing doxycy-
cline (Dox)-controllable EWS/ATF1 alleles9. iPSC-like colonies
were picked up to establish iPSC-like cell lines (Fig. 1a). The
established iPSC-like clones showed elevated activity of alkaline
phosphatase and expressed pluripotency-related genes such as
Nanog and endogenous Oct3/4 (Supplementary Fig. 1a, b). Global
gene expression patterns of iPSC-like cells were similar to those of
control PSCs (Supplementary Fig. 1c, d). DNA methylation
analysis revealed demethylation of Nanog promoter and of Oct3/4
distal enhancer in iPSC-like cells (Supplementary Fig. 1e).
Silencing of the exogenous 4 factors was confirmed in most iPSC-
like clones (Supplementary Fig. 1f). The iPSC-like cell lines often
harbored the chromosomal abnormalities detected in G1297
(Fig. 1b and Supplementary Fig. 1g). Additionally, exome analysis
revealed that candidate mutation sites in G1297 are often mutated
in iPSC-like cell line (Sarcoma-iPSC-G3) (Fig. 1c, Supplementary
Fig. 1h, and Supplementary Table 1). Three independent
sarcoma-iPSC-like clones (G1, G2, and G3) formed teratomas
and contributed to adult chimeric mice (Supplementary Fig. 1i
and Fig. 1d). Together, these results confirm the establishment of
iPSCs that harbor cancer-related genetic abnormalities from
mouse CCS cells in the absence of EWS/ATF1 expression.
Secondary sarcoma development in sarcoma-iPSC mice. We
next examined secondary sarcoma development11,12 in sarcoma-
iPSC chimeric mice by inducing EWS/ATF1. For control
experiments, chimeric mice were generated with embryonic stem
cells (ESCs) and iPSCs, both of which contain EWS/ATF1-
inducible alleles at the identical loci as sarcoma-iPSCs (Supple-
mentary Fig. 2a, b). We confirmed that sarcoma-derived iPSCs
expressed similar levels of EWS/ATF1 with control ESCs and
ETF-iPSCs (ear-tip fibroblast-iPSCs) upon Dox exposure (Sup-
plementary Fig. 2c).
Notably, upon Dox administration, sarcoma-iPSC chimeric
mice developed sarcomas much earlier than ESC- and ETF-iPSC-
derived chimeric mice (Fig. 1e, f and Table 1). Histological
features of secondary sarcomas in the sarcoma-iPSC mice were
similar to those of both primary sarcomas and human CCSs
(Fig. 1g). Furthermore, cell proliferative activity was not
significantly altered in secondary sarcomas (Fig. 1g and
Supplementary Fig. 2d). In sarcoma-iPSC mice, EWS/ATF1
induction resulted in microscopic sarcoma formation in 90% of
mice (9/10) and macroscopic sarcoma development in 40% of
mice (4/10) within 2 weeks (Fig. 1h and Table 1). In sharp
contrast, 2 weeks treatment with Dox for both ESC-derived and
ETF-iPSC-derived chimeric mice resulted in no macroscopic
sarcoma formation (0/12 and 0/11, respectively), and only a few
mice developed microscopic sarcomas (1/12 in ESC mice and 1/
11 in ETF-iPSC mice) (Fig. 1h and Table 1). These results are
consistent with a previous melanoma cloning study by somatic
cell nuclear transfer, in which melanoma-derived chimeric mice
developed secondary melanomas with shorter latency13. In
contrast, sarcoma-iPSC mice that were not given Dox were
vigorous and did not develop any CCS-like sarcomas even at
6 months of age (n= 7), except for one mouse that developed
EWS/ATF1-independent rhabdomyosarcoma (Supplementary
Fig. 2e, f). We also established an iPSC line (sarcoma-iPSC-
K11) from an independent sarcoma cell line (K11) and confirmed
the rapid secondary sarcoma development in the sarcoma-iPSC
chimeric mice (Fig. 1i and Supplementary Fig. 2g). Collectively,
we established a one-step in vivo cancer model using sarcoma-
derived iPSCs.
Cell-type-specific development of secondary sarcomas. Immu-
nohistochemical analysis revealed that EWS/ATF1 is expressed in
various organs and tissues of sarcoma-iPSC mice after Dox
treatment (day 5, Supplementary Fig. 3a). Notably, EWS/ATF1
expression induced secondary sarcomas preferentially at the soft
tissues, such as fascia, subcutaneous tissue, tissue adjacent to the
tendon, and soft tissue outside the eyeballs (Figs. 1e, f, 2a and
Supplementary Fig. 3b). However, despite EWS/ATF1 expression
in a wide variety of organs, such as the intestine, liver, and skin,
EWS/ATF1 did not induce abnormal proliferation in the cells of
these tissues (day 5, Fig. 2b). In contrast, we observed pro-
liferating cells in the soft tissue immediately after Dox treatment
(day 5, Supplementary Fig. 3c, d), indicating that the initiation of
abnormal growth is dependent on cell type.
We next asked why EWS/ATF1 expression fails to induce
cancer development in most cell types. It has been shown that
oncogene expression in somatic cells results in oncogene-induced
senescence (OIS), which prevents cancer development14,15. First,
we examined p53 and p21 expression, a representative OIS
marker16, in multiple organs of sarcoma-iPSC mice after Dox
treatment for 5 days. Notably, an increased number of both p53-
and p21-expressing cells was detectable in accordance with cells
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expressing EWS/ATF1 in multiple organs at day 5 (Fig. 2c, d),
suggesting that OIS occurs in most cell types in sarcoma-
iPSC mice.
To further investigate the effect of EWS/ATF1 expression on
OIS in sarcoma-iPSC-derived differentiated cells, we established
mouse embryonic fibroblasts (MEFs) from sarcoma-iPSC
chimeric embryos, which was followed by puromycin selection.
We found that the sarcoma-iPSC MEFs harbor genetic aberra-
tions, including a part of chromosomal abnormalities and
mutations at Plekhg5 and Alk, which are identical to those in
the secondary sarcomas (Supplementary Fig. 4a). Notably, in
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expressing sarcoma cells, EWS/ATF1-expressing sarcoma-iPSC
MEFs ceased growth and changed morphology into a large and
flat shape (Fig. 3a and Supplementary Fig. 4b–d). The senescence-
associated β-galactosidase (SA β-gal)-positive cell ratio was
significantly higher in EWS/ATF1-expressing MEFs than in
non-expressing MEFs (Fig. 3b), suggesting that EWS/ATF1
induces premature senescence in sarcoma-iPSC MEFs. Consis-
tently, EWS/ATF1 induced the expression of Ink4a, Arf, and
Cdkn1a (p21) in sarcoma-iPSC MEFs (Fig. 3c). Moreover,
knockdown of Trp53 rescued the growth arrest phenotype (Fig. 3d
and Supplementary Fig. 4e), which supports our conclusion that
EWS/ATF1 induces OIS in sarcoma-iPSC MEFs.
Conversely, SA β-gal-positive cells were increased by the
withdrawal of EWS/ATF1 in sarcoma cells (Fig. 3e). Furthermore,
Ink4a and Arf expressions were rapidly increased after the
withdrawal of EWS/ATF1 in sarcoma cells (Fig. 3f), demonstrat-
ing that EWS/ATF1 expression actively prevents senescence in
sarcoma cells. Consistent with the opposing effects of EWS/ATF1
expression on senescence, Il-6, a senescence-associated secretory
phenotype-associated gene was inversely regulated in sarcoma
cells and sarcoma-iPSC MEFs (Supplementary Fig. 4f). Collec-
tively, our results indicate that sarcoma-iPSC mice develop
secondary sarcomas in a cell-type-dependent manner that is
associated with the opposing senescence response to EWS/ATF1.
These results also suggest that cancer-related genetic abnormal-
ities are not sufficient for senescence escape or eventual sarcoma
development in most cell types in this model.
Abnormal cell proliferation starts in peripheral nerves. Taking
advantage of the one-step and cell-type-specific nature of sec-
ondary sarcoma development in sarcoma-iPSC mice, we next
attempted to identify a cell of origin for EWS/ATF1-induced
sarcomas. Histological analysis of sarcoma-iPSC mice shortly
after EWS/ATF1 induction revealed that the abnormal cell growth
often starts around the center of the abdominal wall (Fig. 1e and
Supplementary Fig. 3c). Therefore, we next performed detailed
sequential histological analysis of the abdominal wall after EWS/
ATF1 induction in sarcoma-iPSC mice together with ESC- and
ETF-iPSC-derived mice. We noticed that invasive cancer cell
growth often starts along the course of the peripheral nerves in
the soft tissue and muscle tissue (Fig. 4a). Some early microscopic
lesions resided inside the peripheral nerves and showed bundle-
like patterns (Supplementary Fig. 5a, b). We also observed
microscopic sarcoma development in the gastric wall, which
mimics CCS of the gastrointestinal tract in humans (n= 1/23,
Fig. 4b and Supplementary Fig. 5c)17, and in the mammary gland
(n= 1/23). Consistent with the notion that EWS/ATF1-induced
sarcomas arise from peripheral nerve cells, the early lesions
express S100 protein (Fig. 4c and Supplementary Fig. 5a). We also
found that EWS/ATF1-induced sarcoma cell lines express several
Schwann cell marker genes such as P75NTR, S100b, Mbp, Plp1,
and Pmp22 in vitro (Fig. 4d). These results suggest that S100-
expressing peripheral nerve cells contain a cell of origin for EWS/
ATF1-induced sarcomas.
Schwann cell-related expression profiles in human CCSs. It has
been reported that human CCSs harbor shared properties with
malignant melanomas6. Consistently, previous studies demon-
strated a similarity in the global gene expression patterns of CCSs
and malignant melanomas18. However, we observed that abnor-
mal cell growth often starts along the course of peripheral nerves.
Additionally, we found that EWS/ATF1-induced mouse tumors
and human CCSs often express Schwann cell markers (Supple-
mentary Fig. 5d). Together, these findings raised the possibility
that peripheral nerve cells are a cell of origin for CCSs.
A previous study suggested that EWS/ATF1-induced sarcomas
arise from neural crest derivatives9. Given that key driver
oncogene expression represses the differentiation properties of
cell of origin, we next examined the expression of marker genes of
neural crest derivatives after EWS/ATF1 knockdown in human
CCSs (Fig. 4e, Supplementary Fig. 5e–g). EWS/ATF1 knockdown
led to a significant upregulation of melanocyte-related genes, such
as TYR, MITF, and DCT. However, we also found that a majority
of Schwann cell-related genes were similarly upregulated by EWS/
ATF1 knockdown in human CCS cells, suggesting that CCSs
harbor transcriptional signatures of both melanocytes and
Schwann cells.
Malignant peripheral nerve sheath tumor (MPNST) is a
Schwann cell-derived sarcoma that preferentially occurs in
neurofibromatosis type1 patients19. Of note, both clustering
analysis and principal component analysis using microarray data
revealed that most CCSs resemble more MPNSTs than malignant
melanomas (Fig. 4f and Supplementary Fig. 5h). Moreover, the
genes upregulated (n= 264 probe sets) and downregulated (n=
122 probe sets) in MPNSTs compared to malignant melanomas
were similarly upregulated and downregulated in CCSs, respec-
tively (Fig. 4g). Collectively, our results indicate that human CCSs
Fig. 1 One-step secondary sarcoma development in sarcoma-induced pluripotent stem cells (iPSC) mice. a iPSC-like cells were generated from a murine
clear-cell sarcoma (CCS) cell line (G1297) by introducing four reprogramming factors. Scale bars: 600 µm (upper), 300 µm (lower). b Array comparative
genomic hybridization (CGH) analysis reveals that sarcoma-derived iPSC-like cells (clone G3) share identical chromosomal aberrations with parental
sarcoma cells (G1297). c Candidate mutation sites in sarcoma cells (G1297) and sarcoma-derived iPSC-like cells (clone G3). Exome analysis reveals that
more than 75% of candidate mutation sites in G1297 are overlapped with those in sarcoma-derived iPSC-like cells. d Sarcoma-derived iPSC-like cells
contributed to adult chimeric mice after injection into blastocyst. e Secondary sarcoma development in sarcoma-iPSC mice treated with doxycycline (Dox).
Secondary sarcoma preferentially arose in soft tissue. Left, center of chest and abdominal wall (Dox 1 week). Middle, subcutaneous tissue; right, abdominal
fascia (Dox 4–5 weeks). f Secondary sarcoma developed at the subcutaneous layer (left) in sarcoma-iPSC mouse. Both iPSC G1- and G3-derived mice
developed subcutaneous tumors. Histological analysis reveals that secondary sarcomas resemble primary CCS. EWS/ATF1 expression is detectable in
secondary tumors by immunohistochemistry using hemagglutinin (HA) antibody. Scale bars: 100 µm. g Histology and Ki67-positive cell ratio of primary
CCSs and secondary sarcomas. Scale bars: 50 µm. Primary CCSs were obtained from EWS/ATF1-induced embryonic stem cell (ESC) mice (Rosa-
M2rtTA/Col1a1::tetO-EWS/ATF1-ires-mCherry), while secondary sarcomas were obtained from sarcoma-iPSC mice, which were generated with two
independent iPSC clones (G1 and G3). The mean ± SD of six independent primary and secondary sarcomas are shown, respectively. No significant
difference in the Ki67-positive cell ratio is observed between them (P= 0.4438, two-sided Student’s t test). h Tumor incidence within 2 weeks after Dox
administration in chimeric mice generated with control ESCs, ETF-iPSCs (ear-tip fibroblast-iPSCs), and sarcoma-iPSCs. Sarcoma-iPSC mice developed
secondary sarcomas at a higher incidence and shorter latency than other mice. Pink bar shows the incidence of macroscopic sarcoma, and blue bar shows
the incidence of microscopic sarcoma. i iPSC derivation from an independent sarcoma cell line (K11). A higher incidence and shorter latency of secondary
sarcoma development were observed in sarcoma (K11)-iPSC mice within 2 weeks. Scale bars: 600 µm (left upper), 300 µm (left lower), 200 µm (right
upper), and 50 µm (right lower)
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Table 1 Tumor development after induction of EWS/ATF1




Microscopic tumor Macroscopic tumor Location of tumors
ESC chimeric mice
#3–8 H 1 – –
#2–7 H 1 – –
#2–8 H 1 – –
#3–5 H 1 – –
#3–6 H 1 – –
#3–7 H 1 – –
#2–5 H 2 – –
#2–9 M 2 – –
#2–10 H 2 – –
#2–11 M 2 – –
#2–14 M 2 – –
#2–6 H 2 + – Eye
#2–3 L 4 – –
#3–3 L 4 – –
#3–4 H 4 – –
#2–18 L 4 – –
#2–19 L 4 – –
#2–13 L 4 + – Abdominal wall
#2–17 L 4 + – Subcutaneous tissue
#2–4 M 4 + + Chest wall
#2–12 M 8 + + Chest wall
#2–15 M 8 + + Chest wall
#2–16 M 8 + + Chest wall abdominal wall
#2-1 H 12 – –
#2-2 H 12 – –
#3-1 L 12 – –
#3-2 L 12 – –
7/27 4/27
ETF-iPSC chimeric mice
109 #1-1 M 1 – –
109 #1–2 M 1 – –
109 #1–3 L 1 – –
112 #1–4 H 1 – –
112 #1–5 M 1 – –
112 #1–6 M 1 – –
109 #1–7 H 2 – –
109 #1–8 M 2 – –
109 #1–11 M 2 – –
112 #1–2 L 2 – –
112 #1-1 M 2 + – Eye
109 #1–5 L 4 – –
109 #1–6 L 4 – –
112 #7-1 M 4 – –
109 #1–4 L 4 + – Abdominal fascia
112 #1–3 L 4 + – Subcutaneous tissue
109 #1–9 L 8 – –
109 #1–10 M 8 – –
112 #1–8 L 8 – –
112 #1–9 L 8 – –
112 #1–7 L 8 – –
112 #7-2 L 8 – –
109 #1–12 L 12 – –
109 #1–13 L 12 – –
3/24 0/24
Sarcoma-iPSC chimeric mice
#3 6-3 M 1 – –
#3 6-2 M 1 + – Abdominal wall
#3 4-2 H 1 + – Subcutaneous tissue
#3 5-4 M 1 + – Abdominal wall
#3 6-1 M 1 + – Abdominal wall
#3 3-1 H 1 + + Chest wall abdominal wall eye
#3 10-1 H 1 + + Abdominal wall eye
#3 5-3 H 1 + + Eye subscapula
#3 2-1 H 2 + – Peri-rib
#3 6-4 L 2 + + Abdominal wall
#1 2-1 L 4 + + Eye subcutaneous fascia
1 2-2 L 4 + + Eye
#1 1-1 M 8 – –
#1 1-3 L 8 – –
#3 5-1 M 8 – –
#3 6-5 L 8 – –
#3 7-1 M 8 – –
#1 2-3 L 8 + + Eye
#1 1-2 L 8 + + Eye subcutaneous tissue gastric wall
#3 5-2 L 8 + + Abdominal wall peri-rib eye
#3 7-2 M 8 + + Achilles tendon eye abdominal wall
mammary gland
#3 1-1 M 12 – –
#3 4-3 L 12 – –
15/23 10/23
ESC embryonic stem cell, ETF ear-tip fibroblast, iPSC induced pluripotent stem cell
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exhibit shared properties with Schwann cells in the peripheral
nerves and Schwann cell-derived sarcomas.
Neural crest-derived nerve cells are a cell of origin. We next
employed a genetic approach to determine a cell of origin for
EWS/ATF1-induced sarcomas. For this purpose, Cre or CreERT2
(or CreER) transgene driven by a cell-type-specific promoter was
combined with Rosa26-loxP-stop-loxP (LSL)-rtTA3 allele and
Col1a1:: tetO-EWS/ATF1 to induce EWS/ATF1 upon Dox expo-
sure in a cell-type-specific manner (Fig. 4h and Supplementary
Fig. 5i). Mpz-Cre allele was used for EWS/ATF1 induction in
neural crest derivatives. Similarly, we used Tyr-CreER allele for
the induction in melanocytes and Sox10-CreERT2 allele (Sup-
plementary Fig. 5j) for immature neural crest derivatives as well
as melanocytes and Schwann cells. Additionally, Krox20-Cre allele
was utilized to induce EWS/ATF1 in Schwann cells. After treat-
ment with Dox for 3 months, we found that mice containing
Mpz-Cre allele developed CCS-like sarcomas, indicating that
neural crest-derived cells are a cell of origin for EWS/ATF1-
induced sarcomas (Fig. 4i, j). However, other Cre alleles failed to
induce sarcomas (Fig. 4i), suggesting that cells expressing well-
established markers for differentiated neural crest derivatives do
not give rise to sarcomas after EWS/ATF1 induction.
Tppp3 is a candidate marker for a cell of origin of the sarcoma.
We therefore hypothesized that unclassified neural crest deriva-
tives in peripheral nerves may be a cell of origin for EWS/ATF1-
induced sarcomas. Accordingly, we next searched for candidate
genes that are expressed in cell of origin for EWS/ATF1-induced
sarcomas. For identification of the candidate genes, we used the
following criteria: (1) genes that increase upon nerve cell differ-
entiation, (2) genes that are expressed in nerve cells, but not in
melanocytes. Given that cancer cells often recover the original cell
properties by inhibition of key oncogenic signals, we also extract
(3) genes that increase upon EWS/ATF1 withdrawal in mouse
CCS cells (G1297). According to published microarray data20,21,
we extracted 393 genes, which were highly expressed in mature
sciatic nerves (4 months of age) compared to immature sciatic
nerve (5 days of age) (criterion 1) (cut-off fold change; 4-fold),




















































Fig. 2 Cellular context-dependent senescence response to EWS/ATF1 expression. a Immunostaining of secondary sarcoma in soft tissue using
hemagglutinin (HA) and Ki67 antibodies reveals that EWS/ATF1-expressing cells have high proliferative activity in tumor. Scale bar: 50 µm.
b Immunofluorescence of several organs and tissues in sarcoma-induced pluripotent stem cell (iPSC) chimeric mice given doxycycline (Dox) for 5 days
using HA and bromodeoxyuridine (BrdU) antibodies. HA-positive EWS/ATF1-expressing cells are exclusively negative for BrdU, indicating EWS/ATF1-
expressing cells acquired no malignant proliferation. Scale bars: 50 µm. c Immunostaining for p53 and p21 in multiple organs of sarcoma-iPSC chimeric
mice given Dox for 5 days. Note that p53- and p21-positive cells are frequently observed in the liver, kidney, stomach, and hair follicle. Insets indicate higher
magnification. Scale bars: 100 µm. d p21-positive cells are often overlapped with EWS/ATF1-expressing somatic cells in sarcoma-iPSC mice. Scale
bars: 100 µm
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compared to melanocytes (criterion 2) (cut-off fold change; 10-
fold). We also extracted 86 genes that increase after withdrawal of
EWS/ATF1 expression in sarcoma cells (G1297) (criterion 3)
(cut-off fold change; 5-fold) (Fig. 5a and Supplementary Fig. 6a).
Finally, four overlapping genes in three criteria were regarded as
candidate marker genes for cell of origin for EWS/ATF1-induced
sarcomas. Among four candidate genes, we focused on Tppp3
since remarkable increment of TPPP3 expression was observed by
knockdown of EWS/ATF1 in human CCS cell line (MP-CCS-SY)
(Fig. 5b).
Tppp3 is expressed in peripheral nerve cells of adult mice.
Tppp3 is a tubulin polymerization-promoting protein family
member 3 gene and is expressed in developing tendon sheath in
the embryonic stage22. To determine the Tppp3 expression pat-
tern in adult tissues, we next established Tppp3-EGFP reporter
knock-in mice (Fig. 5c and Supplementary Fig. 6b). Tppp3 was
expressed in bronchial epithelial cells of the lung (Fig. 5d) and
squamous epithelium of the esophagus, which is consistent with
the LacZ expression pattern in the KOMP expression atlas for
Tppp3 (https://www.kompphenotype.org/). Notably, Tppp3 was
also expressed in a subset of cells inside peripheral nerves of the
subcutaneous tissues, which also expressed S100 (Fig. 5e and
Supplementary Fig. 6c), but were not merged with Sox10
(Fig. 5e). S100/Sox10-positive melanocytes in hair follicles were
negative for the reporter (Fig. 5e), affirming that Tppp3 is highly
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expressed in peripheral nerve cells compared with melanocytes in
adult mice. Tppp3 expression was also observed at peripheral
nerves in the muscle tissue (Fig. 5f) and the enteric nerve cells
(Fig. 5g). Notably, Sox10-expressing migrating neural crest cells
and dorsal root ganglion cells at E12.5 were not stained with
enhanced green fluorescent protein (EGFP) (Fig. 5h), suggesting
that Tppp3 is not expressed in early derivatives of neural crest.
To further investigate the distribution of adult Tppp3-
expressing cells in subcutaneous tissue, we established reporter
mice harboring Rosa26-loxP-stop-loxP (LSL)-LacZ23 and Tppp3-
CreERT2 (Rosa26Stop-LacZ/Tppp3CreERT2) (Fig. 5i and Supplemen-
tary Fig. 6d). Four-week-old Rosa26Stop-LacZ/Tppp3CreERT2 mice
were treated with tamoxifen and sacrificed 4 weeks later.
Consistent with the results in Tppp3-EGFP reporter mice,
bronchial epithelial cells of the lung exhibit LacZ staining (Fig. 5j),
while S100-expressing hair follicle cells did not express LacZ
(Fig. 5k). Notably, LacZ staining was detectable in a small subset
of S100-expressing peripheral nerve cells in both soft tissue and
muscle tissue, which corresponds with the location of the initial
abnormal cell growth in sarcoma-iPSC mice (Fig. 4a). LacZ-
positive cells were also observed in the perimysium that
surrounds muscle fibers (Fig. 5l).
Tppp3-expressing cells as a cell of origin of the sarcoma. To
examine whether Tppp3-expressing cells can give rise to EWS/
ATF1-induced sarcomas, we established compound transgenic
mice that harbor Tppp3-CreERT2 allele together with Rosa26-loxP-
stop-loxP (LSL)-rtTA3 allele and Col1a1:: tetO-EWS/ATF1, in
which EWS/ATF1 can be induced with Dox exclusively in Tppp3-
expressing cells after tamoxifen treatment (Fig. 6a). Notably, these
mice developed CCS-like sarcomas after Dox treatment for
3 months (5/14) (Fig. 6b). To further confirm that Tppp3-
expressing cells give rise to sarcomas, we also generated mice
harboring Tppp3-CreERT2 allele and Rosa26-loxP-stop-loxP (LSL)-
EWS/ATF1 allele (Rosa26Stop-E/A/Tppp3CreERT2) in which EWS/
ATF1 can be induced in Tppp3-expressing cells upon tamoxifen
treatment (Fig. 6c and Supplementary Fig. 6e, f). We also gener-
ated transgenic mice containing Sox10-CreERT2 alleles (Rosa26-
Stop-E/A/Sox10CreERT2), where EWS/ATF1 can be induced in Sox10-
expressing cells after tamoxifen injection (Fig. 6c and Supple-
mentary Fig. 6f). Notably, CCS-like sarcomas were observed only
in mice carrying Rosa26Stop-E/A/Tppp3CreERT2 at 3 months after
tamoxifen treatment, while Rosa26Stop-E/A/Sox10CreERT2 mice
never developed the sarcomas (Fig. 6d–f). Collectively, we con-
cluded that Tppp3-expressing cells, but not Sox10-expressing cells,
are a cell of origin for EWS/ATF1-induced sarcomas.
Neural crest-derived cells express both Tppp3 and S100b. We
found that Tppp3-expressing cells can give rise to sarcomas and
early sarcoma lesions often express S100, which suggests that
Tppp3/S100-expressing neural crest-derived cells in peripheral
nerves are a cell of origin for EWS/ATF1-induced sarcomas.
Taking advantage of the taxonomic transcriptome atlas of the
mouse nervous system24, we next investigated transcription
profiles of Tppp3-expressing peripheral nerve cells. The hier-
archical taxonomy based on a single-cell RNA-sequencing
revealed the preferential expression of Tppp3 at clusters of neural
crest-derived cells in the nervous system (Fig. 6g). Notably, a
subset of the Tppp3-expressing clusters expresses S100b. Fur-
thermore, higher levels of Tppp3 were observed in clusters with
neuron-like transcription signatures, which do not express Sox10
(Fig. 6g). Consistent with a previous study demonstrating that
EWS/ATF1 drives tumorigenesis in the Prx1 lineage10, Tppp3-
expressing clusters also expresses Prdx1 (Fig. 6g).
To investigate transcriptional memory of a cell of origin, we
next examined the expression pattern of uniquely overexpressed
genes in human CCSs and MPNSTs using the taxonomic atlas of
the mouse nervous system. Three representative neural crest-
derived tumors, CCSs, MPNSTs, and malignant melanomas, were
compared to extract uniquely overexpressed genes in CCSs (n=
117; cut-off fold change; 2-fold) and MPNSTs (n= 127; cut-off
fold change; 2.5-fold). Notably, expression of MPNST-specific
genes, but not CCS-specific genes, was significantly higher in
Sox10/Krox20-expressing neural crest-derived cell clusters (Fig. 6g
and Supplementary Fig. 6g). These results suggest that MPNSTs,
but not CCSs, harbor transcriptional memory of Schwann cells in
the peripheral nerves.
Finally, we examined a single-cell transcriptome of a Tppp3-
expressing cell. We found that a subset of Tppp3-expressing cells
co-expresses genes that are often highly expressed in CCSs at the
single-cell level. A Tppp3-expressing cell simultaneously expresses
S100b, Ngfr, Pmp22, and Ebf1, whereas Sox10 and Krox20 are
hardly expressed in a Tppp3-expressing cell (Fig. 6h). Collectively,
we propose that Tppp3-expressing and Sox10/Krox20-negative
neural crest-derived peripheral nerve cells are a cell of origin for
EWS/ATF1-induced sarcomas, at least in this transgenic
mouse model.
Cell-type-specific binding patterns of EWS/ATF1. We next
considered the molecular mechanisms for cell type specificity of
sarcoma development. Considering the heterogeneous nature of
Tppp3-expressing cells, it seems technically difficult to isolate
Tppp3-expressing cells that give rise to the sarcoma. Therefore,
Fig. 3 Opposing effects of EWS/ATF1 on cellular senescence depending on cell type. a Sarcoma-induced pluripotent stem cell (iPSC) mouse embryonic
fibroblasts (MEFs) cease proliferation in the presence of doxycycline (Dox). In contrast, G1297 proliferate only in the presence of Dox (ns; not significant,
**P < 0.01, ***P < 0.001, two-sided Student’s t test). Dox concentration is 0.2 µg/ml. The mean ± SD of three independent biological experiments are
shown. b Representative images of senescence-associated β-galactosidase (SA β-gal) staining of sarcoma-iPSC MEF with/without Dox treatment (0.2 µg/
ml, 6 days). SA β-gal-positive cells are frequently observed in the Dox ON condition. SA β-gal-positive ratio of Dox OFF- and Dox ON-sarcoma-iPSC MEFs
are shown in the right panel. Frequency of SA β-gal-positive cells significantly increases with EWS/ATF1 expression (**P < 0.01, two-sided Student’s t test).
The mean ± SD of 10 independent biological experiments are shown, respectively. Scale bars: 200 µm. c A real-time quantitative RT-PCR (qRT-PCR)
analysis for Ink4a, Arf, and Cdkn1a in sarcoma-iPSC MEFs after exposure to Dox (**P < 0.01, ***P < 0.001, two-sided Student’s t test). Data are presented as
the mean ± SD of biological triplicates. The mean expression level of samples at 0 h was set to 1. d Knockdown of senescence-related genes in sarcoma-
iPSC MEFs. Note that knockdown of Trp53 results in escape from growth arrest of Dox-treated sarcoma-iPSC MEFs (***P < 0.001, two-sided Student’s t
test). The mean ± SD of two independent biological experiments are shown, respectively. e Representative images of SA β-gal staining of sarcoma cells
(G1297) with/without Dox treatment (0.2 µg/ml, 3 days). Note that most Dox OFF cells are positive for SA β-gal. SA β-gal-positive ratio of Dox OFF- and
Dox ON-sarcoma cells are shown in the right panel. Frequency of SA β-gal-positive cells significantly increases after withdrawal of EWS/ATF1 expression
(***P < 0.001, two-sided Student’s t test). The mean ± SD of four independent biological experiments are shown, respectively. Scale bars: 200 µm. f A qRT-
PCR analysis for Ink4a, Arf, and Cdkn1a in sarcoma cells after withdrawal of Dox. Sarcoma cells exhibit an increased expression of Ink4a and Arf upon EWS/
ATF1 withdrawal (ns; not significant, *P < 0.05, **P < 0.01, ***P < 0.001, two-sided Student’s t test). Data are presented as the mean ± SD of biological
triplicates. The mean expression level of samples at 0 h was set to 1
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we compared sarcoma cells (G1297) and sarcoma-iPSC MEFs,
two different cell types that share genetic abnormalities, which are
associated with sarcoma development but exhibit opposing
senescence responses and cellular kinetics after EWS/ATF1
induction. We first examined the early transcriptional response
after EWS/ATF1 induction in the two cell types. Sarcoma cells
(G1297, Dox OFF) and sarcoma-iPSC MEFs were harvested at 3,
12, and 48 h after Dox treatment and examined for global gene
expressions. Notably, the early transcriptional response was
considerably different between sarcoma cells and sarcoma-iPSC
MEFs (Fig. 7a). Inversely regulated genes in the two cell types
upon EWS/ATF1 induction often contain cell cycle-associated
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genes, such as Mki67, Ccna2, and Aurka (data not shown), which
is consistent with the opposing cellular kinetics after Dox treat-
ment. Notably, we found a global downregulation of histone-
coding genes in sarcoma-iPSC MEFs while they were generally
upregulated in sarcoma cells upon EWS/ATF1 induction (Sup-
plementary Fig. 7a). Considering that decreased histone levels are
implicated in senescence from yeast to mammals25,26, these
findings further support our conclusion that EWS/ATF1 induc-
tion leads to the opposing responses of senescence in the two
different cell types.
Given that EWS/ATF1 affects gene expression via binding to
cyclic AMP response element (CRE) of the genome using the
DNA-binding domain of ATF18, we compared the distribution of
EWS/ATF1 binding in sarcoma cells (G1297) and sarcoma-iPSC
MEFs at 12 h after Dox treatment by chromatin
immunoprecipitation-sequencing (ChIP-Seq) analysis. Although
there exists common EWS/ATF1 binding sites in the two cell
types (n= 5109), we observed unique binding sites in G1297 and
sarcoma-iPSC MEFs (n= 2981 and 15601, respectively) (Fig. 7b
and Supplementary Fig. 7b, c). Notably, the increased binding of
EWS/ATF1 was associated with increased expression in G1297
(Supplementary Fig. 7d). Indeed, consistent with the premature
senescence phenotype and the increased expression of Ink4a and
Arf in sarcoma-iPSC MEFs, EWS/ATF1 binding was detectable at
Cdkn2a locus in sarcoma-iPSC MEFs but not in G1297 (Fig. 7b).
Moreover, EWS/ATF1 was enriched at a super-enhancer in
G1297 (Supplementary Fig. 7e)27. Together, these results suggest
that the cell-type-specific binding of EWS/ATF1 is responsible for
the cell-type-specific transcriptional profiling.
H3K27ac-pre-marked regions are targets of EWS/ATF1 bind-
ing. We further asked why the EWS/ATF1-binding patterns
were different in the two cell types. We focused on H3K27ac, an
active epigenetic mark, in sarcoma cells (G1297) and MEFs
before EWS/ATF1 induction. ChIP-Seq data for H3K27ac in
both Dox OFF sarcoma cells (sarcoma cells without EWS/ATF1
expression) and wild-type MEFs28,29 revealed that EWS/ATF1
was recruited to H3K27-pre-marked regions in both sarcoma
cells and sarcoma-iPSC MEFs (Fig. 7c and Supplementary
Fig. 7f, g). Furthermore, cell-type-specific binding sites were
differentially pre-marked with H3K27ac in the two cell types: in
Dox OFF sarcoma cells, sarcoma-specific binding sites were
preferentially pre-marked with H3K27ac and less marked at
MEF-specific binding sites (Fig. 7d); this relationship was con-
versed in wild-type MEFs (Fig. 7d). Collectively, these results
suggest that EWS/ATF1 binds to genomic regions pre-marked
with H3K27ac. However, H3K27ac-pre-marked sites did not
always correspond to EWS/ATF1 binding sites (Supplementary
Fig. 7b), which presumably reflects the different location of
binding sites for the enhancer-related transcription factors (TFs)
and ATF1.
EWS/ATF binding in neural crest-related enhancers. An
H3K27ac-marked region often corresponds to an enhancer.
Given that TFs are involved in the establishment of enhancers, we
next tried to identify TFs responsible for cell-type-specific EWS/
ATF1 binding. HOMER (Hypergeometric Optimization of Motif
EnRichment)-known motif analysis revealed a list of TF-binding
motifs at sarcoma-specific and MEF-specific binding sites
(Table 2). We found Creb/Atf and Jun/Fos motifs as the most
enriched motifs in both sarcoma-specific and MEF-specific
binding sites (Table 2), which is consistent with the fact that
EWS/ATF1 binds to the genome through the DNA-binding
domain of ATF18. We also observed unique motifs at each
binding site. Most notably, the unique enriched motifs at
sarcoma-specific binding sites often included motifs of neural
crest-related TFs, such as Ebf1, Sox10, and Nur77 (Nr4a1), while
those at MEF-specific binding sites included motifs of mesench-
ymal cell/connective tissue/embryonic tissue-related TFs, such as
Runx2, Tead4, and Meis1 (Table 2)30–32. These findings suggest
that enhancers of cell of origin are targets of EWS/ATF1 bindings,
which may account for the cell-type-specific patterns of EWS/
ATF1 bindings.
Epigenetic silencing induces growth arrest in sarcoma cells.
Our cell-type-specific sarcoma model demonstrated that cancer
genome requires specific cellular context to exert cancer proper-
ties, and suggested that enhancers in a cell of origin affect the
genomic binding sites of key oncogenic proteins. Finally, we tried
to alter the cancer cell fate by modulating the cell-type-specific
binding pattern of EWS/ATF1. The Krüppel-associated box
(KRAB) is a transcriptional repressor domain that interacts with
histone deacetylase and induces epigenetic silencing33. Therefore,
we attempted to induce silencing at sarcoma-specific EWS/ATF1
binding sites in sarcoma cells by overexpressing KRAB-fused
Ebf1, since the Ebf1 motif is the most abundant motif among
sarcoma-specific motifs for EWS/ATF1 binding (Table 2).
Notably, the introduction of the Ebf1-KRAB fusion gene resulted
in remarkable growth inhibition of sarcoma cells, whereas the
transduction of control KRAB fusion genes did not inhibit the
growth of sarcoma cells (Fig. 7e and Supplementary Fig. 8a).
Importantly, knockdown of Ebf1 did not affect sarcoma cell
growth (Supplementary Fig. 8b), suggesting that enhancer activity
Fig. 4 EWS/ATF1 expression transforms peripheral nerve cells. a Hematoxylin and eosin (HE) staining of sarcoma-induced pluripotent stem cell (iPSC)-
derived chimeric mice treated with doxycycline (Dox) for 3 days (left) or 5 days (right), respectively. Invasive growth of dysplastic cells is often observed
along the course of peripheral nerves in the abdominal wall (arrows) and muscle tissue. Scale bars: 100 µm. b Secondary sarcoma development is found in
Auerbach’s plexus at the gastric wall in sarcoma-iPSC-derived chimeric mice. Scale bar: 100 µm. c Microscopic sarcomas developed in the original clear-
cell sarcoma (CCS) model mice after 6 weeks of Dox treatment. Microscopic tumor cells express S100. Scale bars: 200 µm (upper), 50 µm (lower).
d Reverse transcription-polymerase chain reaction (RT-PCR) of murine EWS/ATF1-induced sarcoma cell lines demonstrates that most cell lines express
Schwann cell-related genes. The number of PCR cycles was 35. e Heatmap of marker gene expression for neural crest derivatives at 48 h after knockdown
of EWS/ATF1 in a human CCS cell line (MP-CCS-SY) by microarray. f Principal component analysis (PCA) analysis of human CCSs, malignant peripheral
nerve sheath tumors (MPNSTs), and malignant melanomas by microarray. Our microarray data included all 8 CCSs and 4 out of 7 MPNSTs along with
published data of 3 MPNSTs (GSE60082) and all 17 melanomas (GSE30812)50,51. g Heatmap showing expression of genes that are up- or downregulated
at least 3-fold in MPNSTs compared to malignant melanomas in CCSs. Color range is shown using a log 2 scale. h A schematic illustration of the genetic
construct for Dox-inducible EWS/ATF1 in neural crest derivatives. Mice with Cre allele were given Dox for 3 months starting at 4 weeks of age. Mice with
CreERT2 (or CreER) allele were given tamoxifen 3 times at 3 weeks of age, followed by Dox administration for 3 months starting at 4 weeks of age. i Tumor
incidence after EWS/ATF1 induction in neural crest derivatives for 3 months. Mice with Mpz-Cre allele developed sarcomas while other mice did not.
j Histology and hemagglutinin (HA) staining of sarcoma tissue in mice with Mpz-Cre allele. The histology resembles human CCSs and EWS/ATF1-induced
sarcomas in mice9. Scale bars: 50 µm
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at Ebf1 binding sites, but not Ebf1 expression itself, has an impact
on the growth of sarcoma cells. Consistent with this, human CCS
cell line MP-CCS-SY exhibited growth inhibition upon the
transduction of KRAB genes fused with SOX10 and BRN2, both of
which are important TFs for neural crest cell differentiation34,35
(Supplementary Fig. 8c).
Mechanistically, we found that Ebf1-KRAB-expressing sarcoma
cells exhibit a reduced enrichment of EWS/ATF1 at the super-
enhancer when compared with the control NANOG-KRAB-
expressing sarcoma cells (Fig. 7f). Moreover, consistent with our
finding that EWS/ATF1 actively prevents premature senescence
in sarcoma cells, SA β-gal-positive cells were increased in Ebf1-
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KRAB-expressing sarcoma cells (Fig. 7g). Consistently, Cdkn1a
and Ink4a, as well as Il-6, were upregulated in Ebf1-KRAB-
expressing sarcoma cells when compared with control NANOG-
KRAB-expressing sarcoma cells (Supplementary Fig. 8d).
Finally, we tested the effect of pharmacologic inhibition of the
super-enhancer in CCS cells using BET bromodomain inhibitor
JQ1. Notably, both mouse and human CCS cells showed reduced
cell growth by JQ1 treatment in vitro (Fig. 7h, i), whereas the
effect was not obvious in Ewing sarcomas that harbor EWS/FLI1
fusion oncogene (Supplementary Fig. 8e, f). The inhibitory effect
of JQ1 treatment on CCS cell growth was confirmed in a
xenograft model of human CCS cells (Fig. 7j). Altogether, these
results demonstrate that enhancers of cell of origin play an
important role in both the development and maintenance of CCS,
suggesting that they could make a promising therapeutic target.
Discussion
Here we showed that sarcoma-iPSC mice exhibit extremely short
latency for secondary sarcoma development after induction of the
key driver oncogene. The fact that invasive growth starts as early
as 5 days in a cellular context-dependent manner indicates that
somatic cells with particular epigenetic regulation immediately
turn into cancer cells in this model. Considering that most in vivo
solid cancer models require considerable latency for cancer
development, this model should provide a unique tool for
studying many aspects of cancer biology. Indeed, taking advan-
tage of the model, we here propose that Tppp3-expressing neural
crest-derived cells are a cell of origin for mouse CCS cells and
epigenetic regulation at the cell of origin affects the binding
patterns of a key driver oncogenic protein, which leads to the
establishment of a sarcoma-specific super-enhancer. Our results
suggest that the epigenetic regulation of cell of origin may pri-
marily play a critical role in the development and maintenance of
cancer cells.
Genetic mutation of either p53 or Ink4a/Arf locus bypasses the
premature senescence induced by oncogenic Ras, demonstrating
that genetic aberration is causative of the escape from senescence.
Notably, we here show that sarcoma-iPSC mice immediately
develop secondary sarcomas from peripheral nerve cells, but
exhibit premature senescence in other tissues upon the induction
of EWS/ATF1. Although the mechanism by which Tppp3-
expressing cells can escape from senescence remains unclear, our
results suggest that the escape from premature senescence is
mediated by the cellular context with distinct enhancer land-
scapes, which highlights the impact of cell-type-related epigenetic
regulation in cancer development. Consistent with this, we
demonstrated that epigenetic silencing at cell-type-specific
enhancers promotes premature senescence and induces a
growth arrest phenotype in sarcoma cells. We propose that epi-
genetic regulations of the cell of origin could be targets for
modulating cancer cell fate. Considering that key oncogenic sig-
nals often use TFs as effectors of the signal transduction, our
findings might provide a general basis for cell type specificity in
cancer development.
It is noteworthy that EWS/ATF1induced sarcomas from
Tppp3-expressing neural crest-derived cells in peripheral nerves.
A previous proteome analysis demonstrated that Tppp3 messen-
ger RNA (mRNA) and protein expression levels increase upon
peripheral nerve cell differentiation, suggesting that more mature
peripheral nerve cells express Tppp320,36. Conversely, in the
present study, EWS/ATF1 expression failed to transform Sox10-
and Knox20-expressing Schwann cells, which suggests that
Tppp3-expressing cells may be a specialized differentiated cell
type of neural crest-derived peripheral nerve cells. Notably, a
single-cell transcriptome of a Tppp3-expressing cell revealed that
a subset of a Tppp3-expressing cells simultaneously expresses
S100b, Ngfr, Pmp22, and Ebf1, which are often highly expressed in
CCSs, whereas Sox10 and Krox20 are hardly expressed in the
Tppp3-expressing cell. Taken together, we propose that Tppp3-
expressing and Sox10-negative neural crest-derived peripheral
nerve cells are a cell of origin for EWS/ATF1-induced sarcomas.
However, it should be noted that CCSs frequently express well-
characterized markers of both Schwann cells and melanocytes,
including SOX10 and TYR. Notably, the taxonomic transcriptome
atlas of the mouse nervous system suggested that oligoden-
drocytes express genes characteristic in neural crest-derived cells
such as Sox10, which raised the possibility that reprogramming
into neural crest-like state could occur even in non-neural crest
derivatives24. It is possible that such reprogramming is associated
with the expression of characteristic genes in a wide range of
neural crest derivatives in CCSs10.
In summary, we established a cell-type-specific one-step in vivo
sarcoma model using sarcoma-iPSCs. Using this unique cancer
model, we determined Tppp3-expressing peripheral nerve cells as
an origin of EWS/ATF1-induced sarcomas, provided insights into
the cell type specificity for cancer development (Fig. 8).
Methods
Vector construction and gene targeting. To target Rosa26-stop-EWS/ATF1 and
Rosa26-stop-rtTA3-ires-Venus alleles, EWS/ATF1-FLAG-HA and rtTA3-ires-Venus
cassettes were inserted into a targeting vector (pRosa26-DEST; obtained from
Addgene)37. For the Sox10-CreERT2, Tppp3-CreERT2, and Tppp3-EGFP knock-in
system, the Red/ET bacterial artificial chromosome (BAC) recombination system
was used to introduce an ires-CreERT2 or EGFP-pA-rox-PGK-EM7-BsdR-pA-rox
cassette into 3′-UTR of Sox10 BAC or Tppp3 BAC, and targeting vectors with a
Fig. 5 Tppp3 as a candidate marker for cell of origin of clear-cell sarcomas. a Venn diagrams for the extraction of candidate genes of a cell of origin of EWS/
ATF1-induced sarcoma. Criteria 1: mature peripheral nerve cells (4 months age)20 vs. immature peripheral nerve cells (5 days age)20, mature cells-high
genes; fold change >4. Criteria 2: peripheral nerve cells20 vs. melanocytes21, mature peripheral nerve cells-high genes; fold change >10. Criteria 3: G1297
doxycycline (Dox) off vs. G1297 Dox on, G1297 Dox off-high genes; fold change >5. Overlapped four genes (Tppp3, Dgat2, Gca, and Plin4) are indicated. b A
real-time quantitative RT-PCR (qRT-PCR) analysis of TPPP3 after knockdown of EWS/ATF1 in a human clear-cell sarcoma (CCS) cell line (MP-CCS-SY)
(***P < 0.001, two-sided Student’s t test). Data are presented as the mean ± SD of biological triplicates. The mean expression level of siControl-treated cells
was set to 1. c A schematic illustration of the genetic construct for visualization of Tppp3 expression. d Immunofluorescence of Tppp3-EGFP homo mice
(5 weeks age). Scale bar: 50 μm. e Green fluorescent protein (GFP) fluorescence (Tppp3) is also detectable in the peripheral nerve of soft tissue around the
abdominal wall (arrows). Note that GFP expression is detectable in S100-positive cells in the peripheral nerve, while S100/Sox10-positive cells in the hair
follicles are negative for GFP. Scale bar: 100 µm. f GFP (Tppp3) expression can be detectable at terminal fibers of peripheral nerves in the muscle tissue.
Scale bar: 50 µm. g GFP (Tppp3) expression in the stomach. S100-positive cells in Auerbach’s plexus express GFP. Scale bar: 50 μm. h GFP (Tppp3)
expression in Sox10-expressing migrating neural crest cells and dorsal root ganglion cells at E12.5. Scale bar: 100 µm. i A schematic illustration of the
lineage tracing for Tppp3-expressing cells. Mice were treated with tamoxifen at 4 weeks old and sacrificed at 8 weeks old. j LacZ staining in bronchial
epithelial cells. Scale bar: 100 µm. k Double staining for LacZ and S100 in the hair follicle. Scale bar: 50 µm. l LacZ-expressing cells are detectable inside
peripheral nerves in the soft tissue (left) and muscle tissue (right) (arrows), which also express S100. LacZ staining is also observed in cells at the
endomysium surrounding muscle fibers (middle). Scale bar: 50 µm (left and right), 100 µm (middle)
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DT-A-negative selection cassette were generated from these BACs. The obtained
vectors were electropolated to V6.5 ESCs. ESCs were cultured with ES media
containing 350 µg/ml G418 (Nacalai) or 15 µg/ml blasticidin S (Bsd, Funakoshi).
Drug-resistant colonies were picked up and expanded. Correctly targeted ES clones
were confirmed by Southern blotting. To generate Rosa-M2rtTA; Col1a1::tetO-
EWS/ATF1-ires-mCherry ESCs, the EWS/ATF1-FLAG-HA-ires-mCherry-pA
sequence was inserted into pBS31, which was electropolated into KH2 ESCs38. The
established ESCs were used to generate chimeric mice by blastocyst injection.
Cell lines. Mouse CCS cell lines (G1297, K11) were established from EWS/ATF1-
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ATF1 type 1 and type 2, respectively. MP-CCS-SY was provided by H. Moritake
(University of Miyazaki, Miyazaki, Japan)39 and KAS was provided by T. Naka-
mura (Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan).
The mouse Ewing sarcoma cell line (SCOS) was established from EWS/FLI1-
inducible mice40. A673 was obtained from ATCC. TC135 was provided by Dr. T.J.
Triche41. Cells were regularly checked for mycoplasma contamination (e-Myco
Mycoplasma PCR Detection Kit, Life Diagnostics).
In vivo experiment. All animal experiments were approved by the CiRA Animal
Experiment Committee and IMSUT Animal Experiment Committee, and the care
of the animals was in accordance with institutional guidelines. EWS/ATF1-indu-
cible mice were treated with 200 μg/ml Dox-containing water and 10 mg/ml
sucrose starting at the age of 4–6 weeks. For the Cre-mediated recombination,
intraperitoneal injection of tamoxifen (2–4 mg/day × 2–4 times) was performed for
mice harboring the CreERT2 (or CreER) system at 3–4 weeks of age.
For xenograft studies, a total of 3 × 106 sarcoma-derived iPS cells were
transplanted to the subcutaneous tissue of NOD/ShiJic-scid Jcl mice (CLEA Japan)
or BALB/cSLC-nu/nu mice (Japan SLC) to induce teratomas. MP-CCS-SY
xenografts were established by injecting MP-CCS-SY cells (5 × 106) in 30%
Matrigel (BD Biosciences) into the flank of 7-week-old female BALB/cSLC-nu/nu
nude mice (Japan SLC). One month after injection, mice with measureable tumors
were divided into cohorts to be treated with JQ1 at 50 mg kg−1 or vehicle (5:95=
dimethyl sulfoxide:10% 2-hydroxypropyl-β-cyclodextrin) once a day for 15 days.
Tumor volume was measured and calculated every 3 days.
iPSC derivation and maintenance. iPSC derivation was performed by utilizing
retroviral vectors (pMX-OCT3/4, pMX-SOX2, pMX-KLF4, and pMX-cMYC,
obtained from Addgene)42. After the transduction of the reprogramming factors,
sarcoma cells and ear tip fibroblasts were cultured in ESC media supplemented
with human recombinant leukemia inhibitory factor (LIF) (Wako), 2-
mercaptoethanol (Invitrogen) and 50 µg/ml L-ascorbic acid (Sigma). The estab-
lished iPSCs were maintained with ESC media supplemented with LIF, 1 μM
PD0325901 (Stemgent), and 3 μM CHIR99021 (Stemgent).
Establishment of sarcoma-iPSC-derived MEFs. After blastocyst injection of
sarcoma-derived iPSCs, chimeric embryos were harvested at E13.5, and MEFs were
derived from the eviscerated and decapitated embryos with 0.25% trypsin. Because
the PGK-Puro-pA selection cassette was placed at the Rosa26M2rtTA knock-in
allele38, MEFs were treated with 1 µg/ml puromycin (Sigma) for 1 week, and
puromycin-resistant MEFs were used for further experiments.
RT-PCR and real-time quantitative RT-PCR. RNA was extracted by using
RNeasy Plus Mini Kit (Qiagen). Up to 1 µg RNA was used for the reverse tran-
scription (RT) reaction into complementary DNA (cDNA). RT-polymerase chain
reaction (RT-PCR) and real-time quantitative PCR were performed using Go-Taq
Green Master Mix and Go-Taq qPCR Master Mix (Promega), respectively. Tran-
script levels were normalized by β-actin (mouse) and GAPDH (human). Ethical
approval for the use of human tumor samples was granted by the ethics committee
of Kyoto University Graduate School and Faculty of Medicine. All patients who
donated tumor samples used in the study provided written, informed consent. PCR
primers are listed in Supplementary Table 2.
Bisulfite genomic sequencing. Bisulfite treatment was performed using EZ DNA
Methylation-Gold KitTM (Zymo Research) according to the manufacturer’s pro-
tocol. Amplified products were cloned into pCR4-TOPO (Invitrogen) and trans-
formed into DH5α. Colonies were randomly selected and sequenced with M13
forward and M13 reverse primers for each gene.
Cell growth assay. Sarcoma cells and MEFs were plated into 12-well culture plates
at a density of 8 × 104 cells/well. The experiment was performed in triplicate, and
each sample was measured twice. The number of cells was measured by automatic
cell counter TC10TM (Bio-Rad). For JQ1-treated cell growth assay, mouse and
human clear-cell sarcoma cell lines (G1297, MP-CCS-SY, KAS) and mouse and
human Ewing sarcoma cell lines (SCOS, TC135, A673) were plated into 96-well
culture plates at density of 1 × 104 cells/well. The experiment was performed in
triplicate, and each sample was measured twice. The number of cells was measured
by using alamarBlue cell viability reagent (Bio-Rad) according to the manu-
facturer’s protocol.
Histological analysis and immunostaining. Tissues and tumor samples were
fixed with 4% paraformaldehyde overnight and embedded in paraffin. Sections
were stained with hematoxylin and eosin using standard protocol. For immunos-
taining, the antibodies used were anti-HA (C29F4) (Cell Signaling; dilution
1:100–500), anti-HA (Roche; dilution 1:50), anti-Ki67 (SP6) (Abcam; dilution
1:100–150), anti-BrdU (BU1/75 (ICR1)) (Abcam; dilution 1:100), anti-MBP
(Abcam; dilution 1:100–200), anti-S100 (Dako; undiluted), anti-SOX10 (R&D;
dilution 1:150), anti-GFP (4B10) (Cell signaling; dilution 1:150), anti-p53 (Ab240)
(Abcam; dilution 1:250), and anti-p21 (HUGO291) (Abcam; dilution 1:100–500).
ALP staining and SA β-gal staining. Cultured cells were washed with phosphate-
buffered saline, fixed, and alkaline phosphatase (ALP) staining and SA β-gal
staining were performed with ALP Staining Kit (Sigma-Aldrich) and Senescence β-
Galactosidase Staining Kit (#9860S, Cell Signaling), respectively, according to the
manufacturer’s protocol.
siRNA transfection. Small interfering RNA (siRNA) transfection was performed
using Lipofectamine RNAi Max (Invitrogen) at 70–80% confluency. The siRNA
targeting the breakpoint of EWS/ATF1 type 1 was used for the transfection9.
Nontargeting siRNA was used as a control41.
Transduction of KRAB-fused TFs. KRAB-fused genes (Ebf1, SOX10, BRN2,
NANOG) and control gene (GFP) were inserted into pMXs retroviral vector. In all,
12.75 µg of these vectors and 5.625 µg of pCMV-VSV-G were transfected into 1 ×
107 competent cells using FuGENE HD (Roche) or PEI Max (PSI), and the viral
supernatant was collected at 72 h after transfection. A total of 1 × 106 of sarcoma
cells were infected using the same amount of viral supernatant for 10 to 12 h.
Array comparative genomic hybridization. Genomic DNA was extracted with
PureLink® Genomic DNA Mini Kit (Invitrogen). Array comparative genomic
hybridization analysis was performed using SurePrint G3 Mouse Genome CGH
Microarray Kit (Agilent) and analyzed using Agilent Genomic Workbench 7.0.
Microarray analysis. Two hundred nanograms of total RNA prepared with
RNeasy Mini Kit was subjected to cDNA synthesis with WT Expression Kit
(Ambion), and the resultant cDNA was fragmented and hybridized to HuGene-
1.0-st-v1 (Affymetrix) and Mouse Gene 1.0 ST Array (Affymetrix). After hybri-
dization, GeneChip arrays were washed and stained by GeneChip Fluidics Station
450 (Affymetrix) and detected by Scanner 3000 TG system (Affymetrix) following
the manufacturer’s standard protocols. The obtained data were analyzed using
GeneSpring GX software (version 13.0, Agilent Technology).
ChIP-sequencing. Anti-HA antibody (Nacalai, mouse monoclonal, HA124) and
anti-acetyl histone H3 (Lys27) (Wako, mouse monoclonal, MABI0309) were used
for the ChIP-Seq analysis. Purified ChIP DNA was used for the generation of
Fig. 6 Tppp3-expressing cells, but not Sox10-expressing cells, give rise to sarcomas. a A schematic illustration of the genetic construct for doxycycline
(Dox)-inducible EWS/ATF1 in Tppp3-expressing cells. CreERT2 driven by Tppp3 promoter was used to transduce EWS/ATF1. Mice were given tamoxifen 3
times at 3 weeks of age, which was followed by Dox administration for 3 months starting at 4 weeks of age. b Five out of 14 mice developed tumors at
4 months of age. c A schematic illustration of the genetic construct for EWS/ATF1 induction from Rosa26 endogenous promoter in Tppp3- and Sox10-
expressing cells (left, upper). Mice were given tamoxifen 3 times at 3 weeks of age and sacrificed after 3 months. d Rosa26stop-E/A/Tppp3CreERT2 mice
developed macroscopic tumors around fascia. e Tumor incidence in mice with/without tamoxifen treatment is shown. Note that mice with Tppp3-CreERT2
allele, but not Sox10-CreERT2 allele developed tumors. f Histology of these mice recapitulates the results of other clear-cell sarcoma (CCS) model mice
(upper panel). EWS/ATF1 expression in the tumor cells is detected by hemagglutinin (HA) immunostaining (lower panel). Scale bars: 50 µm. g Hierarchical
taxonomic atlas of the mouse nervous system by single-cell RNA-sequencing (RNA-Seq) data24. Gene expression of neural crest derivative markers (upper
panel) and CCS-/malignant peripheral nerve sheath tumor (MPNST)-overexpressed genes (lower panel) is shown along the cell-type taxonomy by
heatmap. Neural crest-derived cell types are marked with a pink background. Tppp3 expression is detectable in neural crest-derived clusters with neuron-
like transcriptional signatures (upper panels). Note that most Tppp3-expressing clusters do not express Sox10 or Krox20. h Single-cell expression data of
neural crest-related genes. Heatmap of each row represents expression values from a single cell. A subset of Tppp3-expressing cells co-expresses S100b,
Ngfr, Pmp22, and Ebf1 at the single-cell level, which are often expressed in CCSs. Note that Sox10 and Krox20 are hardly expressed in a Tppp3-expressing
cell. The PSPEP and PSNF nomenclatures of cell types refer to the classification shown in Zeisel et al.24 (mousebrain.org)
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sequencing libraries with TruSeq ChIP Sample Prep Kit (Illumina). The resultant
DNA libraries were assessed on Agilent Bioanalyzer and quantified with KAPA
Library Quantification Kits (Kapa Biosystems). The libraries were sequenced to
generate single-end 109 bp reads using Illumina HiSeq. We analyzed ChIP-Seq data
by mapping the reads using Bowtie2. The sequencing reads were aligned to mouse
genome build mm9 or mm10. We used the MACS43 version 1.4.2 or 2.1.1 peak
finding algorithm to identify regions of ChIP-Seq enrichment over the background
with P value= 1 × 10−9. Super enhancers were identified by H3K27ac with ROSE
pipelines27,44. To analyze and visualize the mapped reads, ngsplot was used45. The
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Fig. 7 Cell-type-specific binding of EWS/ATF1 for sarcoma maintenance. a Microarray analysis of G1297 and sarcoma-induced pluripotent stem cell
(iPSC)-derived mouse embryonic fibroblasts (MEFs) after exposure of doxycycline (Dox). Heatmap indicates that the two cell types respond differently to
EWS/ATF1. Color range is shown using a log 2 scale. b Chromatin immunoprecipitation-sequencing (ChIP-Seq) data using hemagglutinin (HA) antibody
demonstrate that EWS/ATF1 differentially binds to the genome of G1297 and sarcoma-iPSC MEFs. Representative genomic regions are shown. Note that
EWS/ATF binds to Cdkn2 locus only in sarcoma-iPSC MEFs. c ChIP-Seq analysis using HA antibody reveals that EWS/ATF1 binds to the H3K27ac-pre-
marked region in Dox OFF G1297. d ChIP-Seq data for H3K27ac show that sarcoma-specific EWS/ATF1 binding sites possess more H3K27ac marks than
MEF-specific EWS/ATF1 binding sites in G1297 (Dox OFF). Conversely, MEF-specific EWS/ATF1 binding sites possess more H3K27ac marks than
sarcoma-specific EWS/ATF1 binding sites in wild-type MEFs (GSE31039). Blue line indicates H3K27ac enrichment in a sarcoma-specific EWS/ATF1
binding site, and orange line indicates H3K27ac enrichment in a MEF-specific EWS/ATF1 binding site. e Cell growth assay of G1297 introduced KRAB-fused
transcription factors. Ebf1-KRAB transduction to G1297 causes a significant reduction of cell growth (***P < 0.001, two-sided Student’s t test). The mean ±
SD of three independent biological experiments are shown, respectively. f Ebf1-KRAB transduction in G1297 for 48 h results in a significant reduction of
EWS/ATF1 binding at a super-enhancer when compared with control NANOG-KRAB-inducing G1297 (P < 0.001, Mann–Whitney U test). g SA β-gal-
positive ratio is increased by Ebf1-KRAB transduction for 4 days in G1297 (*P < 0.05, **P < 0.01, ***P < 0.001, two-sided Student’s t test). The mean ± SD of
three to eight independent biological experiments are shown, respectively. h BET bromodomain inhibitor JQ1 inhibits the cell growth of G1297 (***P <
0.001, two-sided Student’s t test). The mean ± SD of three independent biological experiments are shown, respectively. i JQ1 inhibits the cell growth of
human CCS cell lines (*P < 0.05, **P < 0.01, ***P < 0.001, two-sided Student’s t test). The mean ± SD of three independent biological experiments are
shown, respectively. j JQ1 treatment suppresses human CCS cell growth in xenograft model (*P < 0.05, **P < 0.01, Mann–Whitney U test). Solid lines in
each conditions indicate the mean and ± SD of each conditions (Vehicle; n= 16, JQ1; n= 12) are shown, respectively
Table 2 HOMER-known motif analysis
Sarcoma-specific binding sites











1e-1014 2618 34.76% 2802.5 7.39% Atf-related
2 Atf7(bZIP)/3T3L1-Atf7-ChIP-Seq
(GSE56872)/Homer
1e-918 2141 28.43% 1983.2 5.23% Atf-related
3 Atf2(bZIP)/3T3L1-Atf2-ChIP-Seq
(GSE56872)/Homer
1e-849 1776 23.58% 1410.8 3.72% Atf-related
4 c-Jun-CRE(bZIP)/K562-cJun-
ChIP-Seq(GSE31477)/Homer
1e-734 1580 20.98% 1282.4 3.38% Atf-related
5 CRE(bZIP)/Promoter/Homer 1e-610 1238 16.44% 912.8 2.41% Atf-related
6 JunD(bZIP)/K562-JunD-ChIP-
Seq/Homer
1e-584 902 11.98% 437.6 1.15% Atf-related
7 Fra1(bZIP)/BT549-Fra1-ChIP-Seq
(GSE46166)/Homer
1e-414 1582 21.00% 2270.4 5.99% Atf-related
8 AP1(bZIP)/ThioMac-PU.1-ChIP-
Seq(GSE21512)/Homer
1e-411 1882 24.99% 3136.4 8.27% Atf-related
9 Atf3(bZIP)/GBM-ATF3-ChIP-Seq
(GSE33912)/Homer
1e-406 1730 22.97% 2719.3 7.17% Atf-related
10 BATF(bZIP)/Th17-BATF-ChIP-Seq
(GSE39756)/Homer
1e-403 1726 22.92% 2720 7.17% Atf-related
11 Fosl2(bZIP)/3T3L1-Fosl2-ChIP-
Seq(GSE56872)/Homer
1e-352 1143 15.18% 1396 3.68% Atf-related
12 Jun-AP1(bZIP)/K562-cJun-ChIP-
Seq(GSE31477)/Homer
1.00E-287 881 11.70% 1007.1 2.66% Atf-related
13 EBF(EBF)/proBcell-EBF-ChIP-Seq
(GSE21978)/Homer




1.00E-105 507 6.73% 823.9 2.17%
15 EBF1(EBF)/Near-E2A-ChIP-Seq
(GSE21512)/Homer




1.00E-95 466 6.19% 762.9 2.01%
17 Atf4(bZIP)/MEF-Atf4-ChIP-Seq
(GSE35681)/Homer
1.00E-90 527 7.00% 970.4 2.56% Atf-related
18 Nkx6.1(Homeobox)/Islet-Nkx6.1-
ChIP-Seq(GSE40975)/Homer












1.00E-60 928 12.32% 2659 7.01% Atf-related
22 FOXP1(Forkhead)/H9-FOXP1-
ChIP-Seq(GSE31006)/Homer




1.00E-48 1655 21.97% 5889.6 15.53%
24 MafA(bZIP)/Islet-MafA-ChIP-Seq
(GSE30298)/Homer
















1.00E-31 1187 15.76% 4275 11.27%
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Exome analysis and direct sequencing. For the exome sequencing, 3 μg of the
genome was extracted with PureLink Genomic DNA Kit. Whole-exome capture
was performed with the SureSelect XT (Agilent Technologies). The exome
libraries were then sequenced (109 bp paired-end reads) using a
HiSeq2500 system (Illumina). The sequenced reads were mapped to the mouse
reference genome (mm10) using Burrows–Wheeler Aligner (bwa-0.7.12)47 after
trimming the adaptor sequences and low-quality bases by cutadapt-1.8.148.
Properly paired reads with a mapping quality of 30 or higher were extracted using
samtools-1.249, duplicate reads were marked using picard-tools-1.134 (https://
broadinstitute.github.io/picard/), and local realignment was performed using
Genome Analysis Tool Kit (GATK-3.4-0) for further analyses. Mutation calling
was performed using scripts in the Genomon-exome pipeline (http://genomon.
hgc.jp/exome/en/index.html). We selected somatic variants by removing the
single-nucleotide polymorphisms (SNPs) and indels that were reported in dbSNP
Build 142 and by removing the overlapping variants that were present in the V6.5,
129, B6, or DBA2 exome data (DRX077372, DRX077363, DRX077364). A list of
the common mutations in G1297 and sarcoma-iPSC#3 is shown in Supplemen-
tary Table 1. For direct sequencing analysis, the PCR product containing the



















1.00E-30 1125 14.94% 4027.9 10.62% Sarcoma-
specific
MEF-specific binding sites










1e-2516 6796 26.36% 1306.8 5.63% Atf-related
2 Atf1(bZIP)/K562-ATF1-ChIP-Seq
(GSE31477)/Homer
1e-2430 7999 31.03% 1895.2 8.16% Atf-related
3 Atf2(bZIP)/3T3L1-Atf2-ChIP-Seq
(GSE56872)/Homer
1e-2415 5702 22.12% 928.2 4.00% Atf-related
4 c-Jun-CRE(bZIP)/K562-cJun-ChIP-
Seq(GSE31477)/Homer
1e-2145 5184 20.11% 858.6 3.70% Atf-related
5 JunD(bZIP)/K562-JunD-ChIP-Seq/
Homer
1e-1716 2922 11.34% 294.1 1.27% Atf-related
6 Atf3(bZIP)/GBM-ATF3-ChIP-Seq
(GSE33912)/Homer
1e-1382 5991 23.24% 1705.1 7.34% Atf-related
7 BATF(bZIP)/Th17-BATF-ChIP-Seq
(GSE39756)/Homer
1e-1367 6005 23.30% 1726.5 7.43% Atf-related
8 Fra1(bZIP)/BT549-Fra1-ChIP-Seq
(GSE46166)/Homer
1e-1345 5400 20.95% 1438 6.19% Atf-related
9 AP1(bZIP)/ThioMac-PU.1-ChIP-Seq
(GSE21512)/Homer
1e-1309 6409 24.86% 1996.5 8.60% Atf-related
10 CRE(bZIP)/Promoter/Homer 1e-1193 3207 12.44% 575.2 2.48% Atf-related
11 Fosl2(bZIP)/3T3L1-Fosl2-ChIP-Seq
(GSE56872)/Homer
1e-1052 3678 14.27% 853 3.67% Atf-related
12 Jun-AP1(bZIP)/K562-cJun-ChIP-
Seq(GSE31477)/Homer
1e-922 2881 11.18% 596.2 2.57% Atf-related
13 Bach2(bZIP)/OCILy7-Bach2-ChIP-
Seq(GSE44420)/Homer
1e-387 1701 6.60% 459.1 1.98%
14 Chop(bZIP)/MEF-Chop-ChIP-Seq
(GSE35681)/Homer
1.00E-297 1603 6.22% 497.1 2.14%
15 Atf4(bZIP)/MEF-Atf4-ChIP-Seq
(GSE35681)/Homer
1.00E-271 1769 6.86% 615.5 2.65% Atf-related
16 CEBP:AP1(bZIP)/ThioMac-CEBPb-
ChIP-Seq(GSE21512)/Homer
1.00E-189 3147 12.21% 1642.2 7.07% Atf-related
17 RUNX-AML(Runt)/CD4+ -PolII-
ChIP-Seq/Homer
































1.00E-93 3410 13.23% 2158.3 9.29%
26 TEAD4(TEA)/Tropoblast-Tead4-
ChIP-Seq(GSE37350)/Homer









1.00E-75 3891 15.09% 2623.1 11.30%
29 NF1(CTF)/LNCAP-NF1-ChIP-Seq
(Unpublished)/Homer
1.00E-65 1052 4.08% 536.5 2.31%
30 Tbx20(T-box)/Heart-Tbx20-ChIP-
Seq(GSE29636)/Homer
1.00E-64 1069 4.15% 549.7 2.37% MEF-
specific
Motifs appearing in sarcoma-specific and MEF-specific EWS/ATF1 binding sites are shown
MEF mouse embryonic fibroblasts, ChIP-seq chromatin immunoprecipitation-sequencing, CRE cyclic AMP response element, HOMER (Hypergeometric Optimization of Motif EnRichment)
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Gene expression analysis in the mouse nervous system. Combinatorial gene
expression patterns of neural crest-derived peripheral nervous system were ana-
lyzed by using the taxonomic transcriptome atlas of the mouse nervous system
(http://www.mousebrain.org/).
PCR primers. Primers used in this study are shown in Supplementary Table 2.
Statistics. For comparison of the real-time quantitative RT-PCR data, Ki67-
positive ratio, SA β-gal-positive ratio, and the cell growth assay, two-sided Stu-
dent’s t test was used for the statistical analysis. Mann–Whitney U test was used for
single-cell RNA-Seq analysis. Mann–Whitney U test was used for xenograft ana-
lysis. Differences were considered statistically significant at P < 0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The ChIP-Seq data have been deposited in the Gene Expression Omnibus database under
the accession code GSE124873. The microarray data have been deposited in the Gene
Expression Omnibus database under the accession code GSE77203. All the other data
supporting the findings of this study are available within the article and
its Supplementary information files and from the corresponding author upon reasonable
request. A reporting summary for this article is available as a Supplementary
information file.
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